Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment to date. Busulfan-based conditioning regimens are commonly used, although high inter-individual variability (IIV) in busulfan drug exposure makes individual dose select...

Full description

Bibliographic Details
Main Authors: Adrin Dadkhah, Sebastian Georg Wicha, Nicolaus Kröger, Alexander Müller, Christoph Pfaffendorf, Maria Riedner, Anita Badbaran, Boris Fehse, Claudia Langebrake
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Pharmaceutics
Subjects:
busulfan
sulfolane
myelofibrosis
population pharmacokinetics
Online Access:https://www.mdpi.com/1999-4923/14/6/1145

Internet

https://www.mdpi.com/1999-4923/14/6/1145

Similar Items